Case Studies

Learn about our work and hear what our clients have to say.

As a CCRM subsidiary, OmniaBio is building on an established foundation and reputation in manufacturing for cell and gene therapies, expanding on a knowledge base and legacy that has been built over a decade. Our teams have collaborated as a CDMO partner working with the following organizations or on the following projects:

Nkarta – in a project that achieved cost-effective manufacturing, under tight timelines, as a CDMO partner for clinical-phase manufacturing of a natural killer cell product.
“We’ve found an ongoing partner” – Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta
DiscGenics – in a collaboration that developed a novel process to enable efficient manufacturing of an allogeneic therapy.
“[The team] really helped us get to where we are today.” – Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics
Avectas – in a project to accelerate the translation of SOLUPORE™ into the clinic. Our teams developed a unique intracellular delivery platform to enable ex vivo cell-based therapies.

“OmniaBio’s culture and adaptive nature, flexibility and communication were excellent.” – Edel O’Toole, Senior Director Project & Vendor Management, Avectas

 

 

The Cystic Fibrosis (CF) Canada Program in Individualized Therapy (CFIT)
The Cystic Fibrosis (CF) Canada Program in Individualized Therapy (CFIT). Learn how our team collaborated with an academic lab at The Hospital for Sick Children to establish a bank of 100 patient-derived iPSC lines and isogenic controls.

“The team has shared valuable expertise with our team, benefiting the project overall.”
– Dr. Christine Bear, The Hospital for Sick Children

Process Development for Scaled-up hESC/hiPSC Manufacturing
Process Development for Scaled-Up hESC/hiPSC Manufacturing
Read about an optimized 14-day manufacturing workflow that produces >1010 cells.
Manufacturing of Pluripotent Stem Cell-Derived Cardiomyocytes for Pre-Clinical Animal Studies
Manufacturing of Pluripotent Stem Cell-Derived Cardiomyocytes for Pre-Clinical Animal Studies
Find out how we worked with a member of the local academic community to translate a cell therapy protocol from bench-scale to bioreactor.
Animal Component Free (ACF) Media Development for Cell Therapies
Animal Component Free (ACF) Media Development for Cell Therapies
Understand how ACF media can achieve comparable performance to serum-containing media.
Contact us to learn more about how we can support your needs at cdmo@omniabio.com.